Story · Medicine & Biotech
Cardiometabolic and Hepatic Outcomes of Incretin-Based Therapies in Patients With Type 2 Diabetes and Coexisting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis of Randomized Controlled Trials
1 outlet · first reported by Cureus on
Type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) commonly coexist and amplify cardiorenal and hepatic risk, yet the combined hepatic and glycemic effect of incretin-based therapy has not been quantified. We conducted a systematic review and meta-analysis of… (Cureus)
Coverage, in order
-
Cardiometabolic and Hepatic Outcomes of Incretin-Based Therapies in Patients With Type 2 Diabetes and Coexisting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) commonly coexist and amplify cardiorenal and hepatic risk, yet the combined hepatic and glycemic effect of incretin-based therapy has not been quantified. We conducted a systematic review and meta-analysis of…
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.